Tissue And Plasma Tumor Mutation Burden (Tmb) As Predictive Biomarkers In The Co.26 Trial Of Durvalumab Plus Tremelimumab (D Plus T) Versus Best Supportive Care (Bsc) In Metastatic Colorectal Cancer (Mcrc).
JOURNAL OF CLINICAL ONCOLOGY（2021）
摘要
61Background: Pembrolizumab was recently granted tissue agnostic FDA accelerated approval for metastatic cancers with TMB≥10 mut/Mb. However, limited data supports immunotherapy in microsatellite s...
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要